Symposium

2025 Early Career Preceptorship Program on Interstitial Lung Disease: Clinical Advances in Fibrosing ILDs – Multidisciplinary Approaches to Optimizing Patient Care

Launch Date
10/04/2025 at 08:00 am EDT
Credit Amount
6.5
Credit Expires
10/04/2025
Location Name Wyndham Garden Lake Buena Vista Disney Springs Area
Address 1850B Hotel Plaza Blvd.
City Lake Buena Vista
State Florida

Faculty

Fernando J. Martinez, MD, MS
Joseph D. Early Chair in Biomedical Research
Vice Chair, Clinical and Translational Research
Academic Chief, Division of Pulmonary, Allergy, and Critical Care Medicine
University of Massachusetts Chan Medical School
Worcester, MA
Deji Adegunsoye, MD, MSc, PhD, FCCP
Assistant Professor of Medicine
Scientific Director, Interstitial Lung Disease Program
University of Chicago Medicine
Chicago, IL
Kerri Aronson MD, MS
Assistant Professor of Medicine
Division of Pulmonary and Critical Care
Weill Cornell Medicine
New York, NY
Corey D. Kershaw, MD, FCCP
Professor of Medicine
Division of Pulmonary and Critical Care Medicine
University of Texas Southwestern Medical Center
Dallas, TX
Joyce S. Lee, MD, MAS, ATSF
Professor
University of Colorado Denver - Anschutz Medical Campus
Aurora, CO
Scott M. Matson, MD
Assistant Professor
Department of Medicine
Division of Pulmonary, Critical Care and Sleep
Kansas Medical Center
Kansas City, KS
Anna Podolanczuk, MD, MS, ATSF
Associate Director, Interstitial Lung Disease Program
Weill Cornell Medicine
New York, NY
Explore By Section
Statement of Need Learning Objectives Financial Support Target Audience Credit Information Disclosure Declaration Obtaining Credit

Statement of Need

OVERVIEW
Rheumatologists, pulmonologists, NPs, PAs, fellows and residents who have been in practice for less than 10 years with an interest in interstitial lung diseases (ILDs) are invited to attend the 2025 Early Career Professional Program on Interstitial Lung Disease (ECPP-ILD). Ideal candidates are committed to improving their diagnostic skills, expanding their understanding of ILDs, and preparing for successful clinical practice. During this intensive 1-day program, participants will attend interactive plenary sessions, join small-group breakouts, and engage in scenario-based case discussions alongside peers and expert faculty. The program emphasizes real-world application, mentorship, and the integration of multidisciplinary perspectives.

ACTIVITY DESCRIPTION
The ECPP-ILD is a 1-day, immersive educational program designed to support rheumatology and pulmonology trainees by advancing their knowledge of ILDs—complex, often progressive pulmonary disorders associated with high morbidity and mortality. Given the challenges in early and accurate diagnosis as well as the heterogeneity of ILD presentation, the program focuses on practical strategies for diagnosis and management in diverse care settings. 

This year’s program, titled “Clinical Advances in Fibrosing ILDs: Multidisciplinary Approaches to Optimizing Patient Care,” will include:

  • Plenary sessions led by expert rheumatologists and pulmonologists covering the latest advancements in ILD diagnosis, treatment, and care coordination 
  • Small-group breakouts where learners engage with faculty in table-top discussions to explore key topics from plenary sessions through real-world clinical scenarios
  • Scenario-based discussions that reinforce evidence-based approaches, diagnostic guidelines, and multidisciplinary collaboration for patient-centered care 

Participants will also explore career development topics such as practice setting selection, geographic impact on compensation, and navigating contract terms. The curriculum is designed to align learners’ goals with their professional environment and improve patient outcomes. 

WHO SHOULD ATTEND
Rheumatologists, pulmonologists, NPs, PAs, fellows and residents who have been in practice for less than 10 years with an interest in interstitial lung diseases (ILDs). The program is especially relevant for trainees entering the workforce who seek mentorship, practical insights, and peer collaboration. Attendees should be prepared to participate actively in case-based discussions and collaborative learning exercises aimed at enhancing their diagnostic acumen and readiness for clinical practice.

Learning Objectives

At the conclusion of this activity, learners will be able to better:

  • Identify the pathophysiology, prevalence, and burden of disease associated with fibrosing ILDs
  • Integrate updated diagnostic guidelines, tools, and best practices to identify fibrosing ILDs earlier and with greater accuracy
  • Implement a multidisciplinary approach to manage common comorbidities and improve disease management of fibrosing ILDs

Financial Support

This activity is supported by an independent medical educational grant from Boehringer Ingelheim Pharmaceuticals, Inc.

Target Audience

Early career rheumatologists and pulmonologists (residents, fellows, early-career physicians)

Credit Information

Jointly Accredited Provider

In support of improving patient care, CME Outfitters, LLC, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

Physicians (ACCME) 6.5

CME Outfitters, LLC, designates this live activity for a maximum of 6.50 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

ABIM MOC 6.5

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 6.50 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

MIPS Improvement Activity

Completion of this accredited CME activity meets the expectations of an Accredited Safety or Quality Improvement Program (IA_PSPA_28) for the Merit-based Incentive Payment Program (MIPS). Clinicians should submit their improvement activities by attestation via the CMS Quality Payment Program website.

Royal College MOC

Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.

Disclosure Declaration

It is the policy of CME Outfitters, LLC, to ensure independence, balance, objectivity, and scientific rigor and integrity in all of their CE activities. Faculty must disclose to the participants any relationships with commercial companies whose products or devices may be mentioned in faculty presentations, or with the commercial supporter of this CE activity. CME Outfitters, LLC, has evaluated, identified, and mitigated any potential conflicts of interest through a rigorous content validation procedure, use of evidence-based data/research, and a multidisciplinary peer review process. The following information is for participant information only. It is not assumed that these relationships will have a negative impact on the presentations.

Dr. Martinez reports the following financial relationships:

Advisory Board (All without honoraria): Boehringer Ingelheim; Chiesi USA, Inc.; and GSK

Consultant (All without honoraria): AstraZeneca; Boehringer Ingelheim; Chiesi USA, Inc.; Excalibur Pharmaceuticals, Inc.; Gossamer Bio; GSK; Lung Therapeutics, Inc.; RS BioTherapeutics, Inc.; Tvardi Therapeutics; and TwoXR Therapeutics

Grants: Steering Committees (No honoraria but travel support): Boehringer Ingelheim; Bristol Myers Squibb Company; Chiesi USA, Inc.; DevPro Biopharma; GSK; Nitto BioPharma Inc.; Respivant Sciences; Roche; and Vicore Pharma

Other financial or material support: DSMB for Endeavor BioMedicines and Pliant Therapeutics, Inc.

Dr. Adegunsoye reports the following financial relationships:

Advisory Board: Avalyn Pharma Inc.; Boehringer Ingelheim; Inogen, Inc.; and PureTech Health

Consultant: AbbVie Inc.; Avalyn Pharma Inc.; Baxter; Boehringer Ingelheim; Brainomix; Inogen, Inc.; PatientMpower; PureTech Health; and Roche

Grants and Research Support:  American College of Chest Physicians (CHEST); National Institutes of Health (NIH); and Pulmonary Fibrosis Foundation (PFF)

Speakers Bureau: Boehringer Ingelheim

Dr. Aronson reports the following financial relationships:

Advisory Board: PureTech Health

Grants and Research Support: American Lung Association; National Institutes of Health (NIH)/National Heart, Lung, and Blood Institute (NHLBI); and Scleroderma Foundation

Dr. Kershaw reports no financial relationships to disclose.

Dr. Lee reports the following financial relationships:

Advisory Board: AbbVie Inc.; AstraZeneca; Eleven P15; Elima Therapeutics Inc.; Foresee Pharmaceuticals Co., Ltd.; Gatehouse Bio; MannKind Corporation; Mediar Therapeutics; and Syndax Pharmaceuticals

Grants: National Institutes of Health (NIH)

Research Support: Site PI for clinical trials – Avalyn Pharma Inc.; Bristol Myers Squibb Company; FibroGen, Inc.; GSK; Pliant Therapeutics, Inc.; and Tvardi Therapeutics

Other financial or material support:
DSMB: Pulmovant and United Therapeutics Corporation
Steering Committee: Avalyn Pharma Inc. and Boehringer Ingelheim
Section Editor: Merck & Co., Inc.

Dr. Matson reports no financial relationships to disclose.

Dr. Podolanczuk reports the following financial relationships:

Advisory Board: Boehringer Ingelheim; Brainomix; Nelum Pharma; and Trevi Therapeutics

Consultant: Avalyn Pharma Inc.; Boehringer Ingelheim; Eisai; IMVARIA Inc.; Plaint Therapeutics, Inc.; PureTech Health; Regeneron; Pharmaceuticals Inc.; United Therapeutics Corporation; and Veracyte, Inc.

Grants: Brainomix; National Heart, Lung, and Blood Institute (NHLBI); and Three Lakes Foundation LLC

Research Support: Avalyn Pharma Inc.; GSK; Pliant Therapeutics, Inc.; United Therapeutics Corporation; and Vida

Speakers Bureau: Boehringer Ingelheim; Managed Healthcare Executive; PeerDirect; Raymond James; and Vida

The following individuals have no financial relationships to disclose: 

Jeffrey Helfand, DO (Peer Reviewer)
Rebecca Vargas-Jackson, MD (Peer Reviewer)
Susan Perry (Planning Committee)
Warren Beckman (Planning Committee)
Scott J. Hershman, MD, FACEHP, CHCP (Planning Committee)
Sandra Caballero, PharmD (Planning Committee)
Sharon Tordoff (Planning Committee)

*All identified conflicts of interest have been mitigated.

Unlabeled Use Disclosure
Faculty of this CME/CE activity may include discussions of products or devices that are not currently labeled for use by the FDA. The faculty have been informed of their responsibility to disclose to the audience if they will be discussing off-label or investigational uses (any uses not approved by the FDA) of products or devices. CME Outfitters, LLC, the faculty, planners, and reviewers do not endorse the use of any product outside of the FDA labeled indications. Medical professionals should not utilize the procedures, products, or diagnosis techniques discussed during this activity without evaluation of their patient for contraindications or dangers of use.

Obtaining Credit

Post-tests, credit request forms, and activity evaluations must be completed online (requires free account activation), and participants can print their certificate or statement of credit immediately (0% pass rate required). This website supports all browsers except Internet Explorer for Mac.

Questions about this activity?

Call us at 877.CME.PROS (877.263.7767).

EC-007-100425-25

2025 Early Career Preceptorship Program on Interstitial Lung Disease: Clinical Advances in Fibrosing ILDs – Multidisciplinary Approaches to Optimizing Patient Care
Event Date: 10/04/2025 at 08:00 am EDT
Register